Investors tracking TNXP stock price forecast should note its recent bullish divergence in RSI, which could hint at short‑term upward momentum if FDA‑related news breaks in Q Tonix Pharmaceuticals Holding has a market capitalisation of US$523m and burnt through US$65m last year, which is 13% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted. Tonix Pharmaceuticals (TNXP) ha anunciado un split inverso de acciones 1-por-100 con efecto el 5 de febrero de 2025. Esta acción corporativa tiene como objetivo cumplir con el requisito de precio mínimo de oferta de $1.00 del NASDAQ para mantener la cotización. La empresa conservará su símbolo de negociación 'TNXP' bajo un nuevo número CUSIP (890260839). TNXP stock price forecast remains dependent on trial outcome probabilities, with Bayesian models giving a 62% success rate for its lead candidate.